Therapeutic potential of adenosine receptor antagonists and agonists
- 16 August 2007
- journal article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 17 (8) , 979-991
- https://doi.org/10.1517/13543776.17.8.979
Abstract
(2007). Therapeutic potential of adenosine receptor antagonists and agonists. Expert Opinion on Therapeutic Patents: Vol. 17, No. 8, pp. 979-991.Keywords
This publication has 44 references indexed in Scilit:
- Rescue of p53 Blockage by the A2A Adenosine Receptor via a Novel Interacting Protein, Translin-Associated Protein XMolecular Pharmacology, 2006
- Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injuryJournal of Clinical Investigation, 2006
- Effect of Novel A2AAdenosine Receptor Agonist ATL 313 onClostridium difficileToxin A-Induced Murine Ileal EnteritisInfection and Immunity, 2006
- The Ubiquitin-Specific Protease Usp4 Regulates the Cell Surface Level of the A2a ReceptorMolecular Pharmacology, 2006
- Adenosine receptors: promising targets for the development of novel therapeutics and diagnostics for asthmaFundamental & Clinical Pharmacology, 2005
- Heterotrimeric G Protein-independent Signaling of a G Protein-coupled ReceptorJournal of Biological Chemistry, 2005
- The ‘danger’ sensors that STOP the immune response: the A2 adenosine receptors?Trends in Immunology, 2005
- Adenosine in Tissue Protection and Tissue RegenerationMolecular Pharmacology, 2005
- The future of pharmacologic stress: selective a2a adenosine receptor agonistsThe American Journal of Cardiology, 2004
- Pharmacology of 2-cyclohexylmethylidenehydrazinoadenosine (WRC-0470), a novel, short-acting adenosine A2A receptor agonist that produces selective coronary vasodilationDrug Development Research, 1997